Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Ospedale San Raffaele S.r.l.
Sponsor

Ospedale San Raffaele S.r.l.

Italy Via Olgettina 60, 20132 Milan, Italy

About the sponsor

Ospedale San Raffaele S.r.l. is involved in clinical research across several cancer and blood disorder areas, with activity spanning solid tumors and hematologic malignancies. Its studies include chronic lymphocytic leukemia, muscle-invasive bladder cancer, prostate cancer, head and neck cancer, non-small cell lung cancer, and intrahepatic cholangiocarcinoma.

  • Chronic lymphocytic leukemia
  • Prostate cancer and clinically relevant prostate cancer
  • Muscle-invasive bladder cancer
  • Head and neck cancer and non-small cell lung cancer
  • Intrahepatic cholangiocarcinoma

Research activity also includes biomarker-driven approaches, imaging for tumor detection, and perioperative or combination strategies in oncology.

About Specializations

Ospedale San Raffaele S.r.l. runs clinical trials in conditions such as Chronic lymphocytic leukaemia, Prostate cancer, Gastric cancer, Pancreatic carcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

31 clinical trials

Gastric cancer+1

Recruiting

Comparing Remimazolam and Propofol for Deep Sedation in Patients Undergoing Endoscopic Ultrasound for Gastric and Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Propofol
  • Sponsor:Ospedale San Raffaele S.r.l.

Migraine

Recruiting

Study on Eptinezumab for Migraine: Understanding How It Works and Finding Patient Response Markers for Migraine Sufferers

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Eptinezumab
  • Sponsor:Ospedale San Raffaele S.r.l.

Chronic lymphocytic leukaemia+1

Recruiting

Study of Ibrutinib and Obinutuzumab for Patients with Chronic Lymphocytic Leukemia Who Have Not Received Treatment Before

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Ospedale San Raffaele S.r.l.

Chronic lymphocytic leukaemia

Recruiting

Study of Venetoclax, Ibrutinib, and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Venetoclax
  • Sponsor:Ospedale San Raffaele S.r.l.

Progressive multiple sclerosis

Recruiting

Study on Human Fetal Neural Precursor Cells and Tacrolimus for Patients with Progressive Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Ospedale San Raffaele S.r.l.

Heart valve operation

Recruiting

Study on the Use of Landiolol Hydrochloride and Sodium Chloride for Patients Undergoing Mitral Valve Surgery to Prevent Low-Cardiac Output Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ospedale San Raffaele S.r.l.

Cholangiocarcinoma

Recruiting

Study of Radioembolization Combined with Cisplatin, Gemcitabine and Durvalumab Treatment in Patients with Unresectable Liver Cholangiocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Ospedale San Raffaele S.r.l.

Immunoglobulin G4 related disease

Recruiting

Study on Abatacept for Patients with IgG4-Related Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Ospedale San Raffaele S.r.l.

Cardiogenic shock

Recruiting

Study on Cangrelor and Bivalirudin for Patients with Heart Attack-Related Cardiogenic Shock or Cardiac Arrest on VA-ECMO Support

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Ospedale San Raffaele S.r.l.

Multiple sclerosis+1

Recruiting

Study on the Effects of Ozanimod in Patients with Relapsing-Remitting Multiple Sclerosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ozanimod Hydrochloride
  • Sponsor:Ospedale San Raffaele S.r.l.

HIV infection

Recruiting

Study on HIV-1 Patients: Effects of Rilpivirine and Dolutegravir After Stopping Antiretroviral Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dolutegravir
  • Sponsor:Ospedale San Raffaele S.r.l.

Dilated cardiomyopathy

Recruiting

Study on Anakinra for Treating Inflammatory Dilated Cardiomyopathy in Patients: Evaluating Efficacy and Safety of Anakinra with Standard Care vs. Standard Care Alone

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anakinra
  • Sponsor:Ospedale San Raffaele S.r.l.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.